Tobacco Cessation Interventions

Tobacco cessation interventions are evidence-based practices designed to help individuals discontinue all forms of tobacco use, encompassing behavioral counseling, pharmacotherapy, and their combination, delivered across clinical and community settings.

Also Called: Smoking cessation interventions, tobacco treatment, tobacco dependence treatment, quit smoking programs, nicotine addiction treatment, tobacco use cessation.

Classification of Interventions

Tobacco cessation interventions are categorized by modality and intensity. The classification below reflects the three main evidence-based approaches, as supported by Cochrane systematic reviews ^{[1]A1a[2]A1a[3]A1a[4]A1a[5]A1a}.

These interventions are indicated for all tobacco users, including those who smoke cigarettes, use smokeless tobacco, or use other tobacco products. The choice of intervention depends on the individual's readiness to quit, preferences, and prior quit attempts, with combined therapy generally yielding the highest abstinence rates ^[2]A1a[4]A1a.

Clinical Significance

Tobacco use remains the leading preventable cause of death worldwide, and cessation interventions are among the most cost-effective preventive health services, significantly reducing the risk of tobacco-related morbidity and mortality. Systematic reviews demonstrate that even brief interventions by oral health professionals can increase abstinence rates by 71% (OR 1.71) ^[1]A1a, and behavioral support in dental settings yields a 1.86-fold increase in quit rates (RR 1.86, 95% CI 1.01 to 3.41) ^[2]A1a.

Understanding the neurobiological mechanisms underlying nicotine dependence provides the foundation for effective cessation interventions.

Pearl: Interventions are effective across diverse populations, including dental patients, young people, and those with substance use disorders, as supported by Cochrane reviews ^{[2]A1a[3]A1a[4]A1a}.

The mechanisms sustaining tobacco use are both neurobiological and psychosocial, with nicotine driving dependence through dopamine release in the mesolimbic pathway, while social and emotional contexts reinforce the behavior. In populations with substance use disorders (SUDs), the interplay is particularly strong: tobacco use intertwines with other substance use, heightening cravings and impacting efforts to remain abstinent ^[7]D5.

Psychosocial Functions of Tobacco

Qualitative evidence from people in SUD treatment reveals that tobacco serves multiple psychosocial functions that reinforce dependence. Smoking is a coping mechanism for stress, a tool for social connection, and a component of personal identity ^[7]D5[8]D5. For women with SUDs, these functions are amplified by intersecting marginalized identities, and smoking also serves as a response to stigmatization ^[8]D5. The behavior is not merely a habit but a deeply embedded psychosocial strategy that complicates cessation.

Barriers to Cessation

Physiological withdrawal symptoms, irritability, craving, anxiety, are a primary barrier ^[7]D5. Equally important are psychosocial barriers: using tobacco as a coping mechanism, reliance on smoking for social bonding, and limited cessation support within treatment programs and social environments ^[7]D5. Stigmatization around smoking further hinders quitting, as women report feeling judged ^[8]D5. Clinicians themselves face barriers, including organizational lack of support and tobacco-related misconceptions ^[8]D5.

Reinforcement Cycle

The qualitative data describe a reinforcement cycle: tobacco use heightens cravings for other substances, leading to increased use of both, which in turn strengthens tobacco dependence ^[7]D5. This cycle is particularly difficult to break without integrated interventions that address both the pharmacological addiction and the psychosocial functions.

Implications for Intervention

These mechanisms explain why effective tobacco cessation interventions must go beyond nicotine replacement. Integrating pharmacological interventions (e.g., nicotine replacement therapy) with psychosocial and behavioral counseling and social support can address the biological and psychosocial drivers simultaneously ^[7]D5[8]D5. Tailoring interventions to gendered experiences, such as providing non-stigmatizing counseling and alternative coping strategies for women, may improve outcomes ^[8]D5.

The mechanisms described here, the interplay of nicotine dependence, psychosocial reinforcement, and systemic barriers, directly underlie the epidemiology of tobacco use, the high prevalence among SUD populations, and the risk factors that will be discussed in the next section.

Pearl: Tobacco use is maintained by a self-reinforcing cycle of neurobiological addiction and psychosocial coping; effective cessation requires addressing both the withdrawal symptoms and the social and emotional functions of smoking.

The pathophysiologic mechanisms of nicotine addiction operate within populations that bear a disproportionate burden of tobacco use. Approximately 15% of young people smoke in developing countries (with wide variation) and 26% in the UK and USA ^[3]A1a. Among adults, global prevalence remains high: in India, 28.6% of adults use tobacco ^[17]B2a, and in pediatric emergency departments, 33.9% of parents accompanying children are smokers ^[15]C4.

Global Burden and Demographics

Tobacco use is concentrated among disadvantaged and vulnerable groups. People living with HIV are two to three times more likely to smoke than the general population ^[9]A1b. Persons with schizophrenia and related psychotic disorders smoke more and have twice the rate of mortality, with a 10- lower life expectancy ^[10]A1b. Among Indian cancer patients, 74% continue tobacco use after diagnosis, with 50% smoking and 34% using smokeless tobacco ^[17]B2a.

Risk Factors for Tobacco Use and Continued Use

Multiple risk factors predispose to tobacco initiation and impede cessation. The table below summarizes the main factors with their associated effect sizes.

Among young people, interventions that include motivational enhancement increase quit rates by 60% (RR 1.60, 95% CI 1.28-2.01) ^[12]A1a, this underscores the importance of targeting risk factors early. In military populations, behavioural and pharmacological interventions yield short-term (≤3 months) odds of cessation 2.03 (95% CI 1.49-2.77) and long-term (≥6 months) OR 1.53 (95% CI 1.12-2.09) ^[16]A1a.

Temporal Trends and Special Populations

Tobacco prevalence is declining in some high-income countries but remains high in low- and middle-income settings. The prevalence of continued use after cancer diagnosis has not significantly decreased, highlighting the need for integrated cessation services in oncology ^[17]B2a. People living with HIV in sub-Saharan Africa have particularly high tobacco use rates, with studies ongoing to test phone-based interventions ^[13]D5.

Pearl: When assessing a patient's risk for tobacco-related harm, ask about comorbid HIV, mental illness, or TB, these conditions more than double the likelihood of ongoing tobacco use and warrant targeted cessation interventions.

Controversies and Guideline Disagreement

Beyond the robust epidemiologic associations with psychosis, substance use, and ethnic disparities, the clinical presentation of tobacco use disorder encompasses a spectrum of dependence severity, motivation to quit, and comorbidity burden that directly shapes intervention strategy. The patient who smokes is not a single entity; heterogeneity in nicotine metabolism, psychiatric comorbidity, and cultural context creates distinct clinical phenotypes that clinicians must recognize to tailor cessation counseling.

Patterns of Tobacco Use

Use patterns vary by population. Among US adults with psychosis, past-month any tobacco use is 41.3% vs 27.7% in those without psychosis (adjusted risk ratio 1.49) ^[18]C4. Dual cigarette and e-cigarette use is 13.5% vs 10.1%, and polycombustible plus noncombustible tobacco use reaches 22.1% vs 12.4% ^[18]C4. In contrast, Hispanic smokers along the US/Mexico border are typically light smokers with low nicotine dependence, a high number of past quit attempts, and limited use of cessation aids ^[21]C4. Among American Indian and Alaska Native (AIAN) communities, 92% of survey respondents were aware of tobacco risks and 76% considered it a community problem, yet only 29% had any knowledge of pharmacogenomics as a tool for cessation ^[22]C4.

Dependence Severity

Nicotine dependence is more severe in patients with psychosis. The mean nicotine dependence score (PATH Study) was 54.6 vs 49.5 ^[18]C4. This elevated dependence drives higher rates of poly-use and makes unaided quitting less likely. In a cohort from an Indian tobacco cessation clinic, 23.14% of participants had quit at 6 months and 74.38% had reduced use, but the majority received only behavioral counseling (65.35%) rather than combination therapy ^[24]C4.

Motivational Stage and Prior Quit Attempts

Many patients present with a history of multiple quit attempts but without sustained success. Only one in three current smokers with schizophrenia reported that their primary care provider or psychiatrist had assisted them in obtaining medications for tobacco cessation ^[20]C4. This missed opportunity reflects a gap between the prevalence of quit attempts and the delivery of evidence-based pharmacotherapy. Brief interventions, as short as 1 minute, increase the quit attempt rate threefold, but are inconsistently delivered in settings such as emergency rooms ^[19]C4.

Special Populations

Red Flags

Certain clinical presentations should prompt intensified intervention. Patients with psychotic disorders who smoke heavily underestimate their lung cancer risk: among older adults with schizophrenia who met lung screening criteria, >50% believed they had low risk ^[20]C4. This misperception, combined with infrequent delivery of cessation medications, represents a critical missed opportunity. Similarly, in AIAN communities, concerns about genetic material handling and result dissemination require transparent communication before pharmacogenomics-based approaches can be trusted ^[22]C4.

Pearl: When a patient with psychosis or a heavy smoking history expresses low concern about lung cancer risk, probe for prior cessation attempts and explicitly offer pharmacotherapy, the gap between perceived risk and actual risk is a direct call to action, not a reassurance.

Atypical Presentations

Not all tobacco use presents as daily cigarette smoking. Smokeless tobacco use, common in rural Appalachia, is often underrecognized by clinicians in non-dental settings. Emergency room nurses trained in a brief (1-minute) Ask-Advise-Refer strategy increased their motivation and self-efficacy to address smokeless tobacco, but the intervention is rarely delivered ^[19]C4. Clinicians should routinely ask about all forms of tobacco, including chewing tobacco, snus, and dissolvables, particularly in regions with high smokeless prevalence.

Identify tobacco exposure

Establish whether the patient currently uses tobacco, the product used (cigarettes, smokeless tobacco, or other tobacco products), frequency of use, duration, and time since last use. Assessment should include patients with cancer, HIV, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), diabetes, serious mental illness, psychosis, pregnancy, substance-use disorders, and transplant history because tobacco exposure and cessation needs may be clinically important in each setting ^{[17]B2a[18]C4[31]B2c[38]C4[69]B3b[73]C4[79][82]}. In India, a systematic review identified 20 observational studies of continued smoking, smokeless-tobacco use, or both after cancer diagnosis; the review contextualized this problem against an adult tobacco-use prevalence of 28.6% ^[17]B2a.

For patients with cancer, document tobacco use at diagnosis and at each subsequent clinical encounter. Continued use after diagnosis is sufficiently common to warrant active reassessment rather than assuming cessation ^[17]B2a. Cessation around diagnosis is clinically consequential: an umbrella review reported mortality reductions of 15–29% in lung cancer, 20% in head and neck cancer, and 24% in colorectal cancer among patients who quit after diagnosis, with suggestive benefits in breast, bladder, and gastrointestinal cancers ^[28]D5.

Characterize nicotine dependence and cessation history

Record cigarettes or tobacco units per day, time to first use, craving, withdrawal symptoms, use in restricted settings, unsuccessful quit attempts, longest abstinence interval, prior counseling, and prior pharmacotherapy. Assess motivation and the intended quit horizon; in a COPD registry, intention to quit within the next 30 days was the primary behavioral outcome examined in relation to respiratory symptoms and disease-severity markers ^[38]C4. Document whether the patient is preparing to quit, has recently quit, or is maintaining abstinence. Long-term follow-up is relevant because a prospective five-year study reported that 29.6% of the 267 participants followed remained abstinent at five years after cessation care ^[81].

Evaluate all tobacco products and concurrent substance use. Smoking prevalence in people receiving treatment for alcohol or other drug dependence is reported to be two to four times that of the general population, and a Cochrane review evaluated whether tobacco-cessation treatment can be delivered concurrently without compromising recovery from other addictions ^[4]A1a. Patients should therefore not be excluded from tobacco assessment because they are in substance-use treatment or recovery ^[4]A1a.

Assess psychiatric, reproductive, and medical comorbidity

Screen for depression, anxiety, psychosis, serious mental illness, and other factors that may affect readiness, adherence, withdrawal, or relapse. A nationally representative study compared tobacco-product use, nicotine-dependence severity, and cessation methods in community-dwelling adults with and without psychosis ^[18]C4. In an integrated-care cohort, use of cessation pharmacotherapy was examined among smokers with type 2 diabetes with versus without serious mental illness ^[69]B3b. These populations require coordinated assessment rather than a presumption that psychiatric illness precludes cessation treatment ^{[4]A1a[18]C4[69]B3b}.

For patients who are pregnant or planning pregnancy, document prepregnancy smoking, current prenatal smoking, depression or anxiety, and cessation by late pregnancy. A population-based analysis of 34,633 women with live births examined these measures according to reported depression or anxiety ^[73]C4. Postpartum assessment should also consider depressive symptoms because a 2015–2020 analysis of 218,128 PRAMS participants evaluated the association between tobacco smoking and postpartum-depression symptom severity ^[36]C4.

Assess tobacco-related disease burden and treatment context, including respiratory symptoms and pulmonary function when COPD is suspected, diabetes control, TB status, cancer diagnosis, and transplant status. In TB care, an integrated intervention linked cessation support with directly observed therapy, and a related multicenter study evaluated effects on health-related quality of life among 120 Malaysian patients who smoked at TB diagnosis ^[11]B2b[80]. After lung transplantation, tobacco resumption was reported in 4% of one retrospective cohort; COPD, shorter pretransplant cessation duration, and the pack-year–cessation index were associated with post-transplant use ^[79].

Verify abstinence when clinically or methodologically important

Self-reported abstinence may be supplemented by biochemical testing when confirmation affects clinical decision-making, research validity, or transplant assessment. In a randomized trial among people with HIV in South Africa, abstinence at 6 months was self-reported and biochemically validated using exhaled-breath carbon monoxide and urine cotinine ^[26]A1b. The trial randomized 280 participants with HIV who smoked to intensive behavioral counseling alone or counseling plus combination nicotine replacement therapy consisting of nicotine patches and gum ^[26]A1b.

Document access, engagement, and follow-up needs

Record barriers to cessation care, including geographic dispersion, mental-health symptoms, limited resources, hospitalization transitions, and digital-access or engagement problems. A randomized-trial protocol in young cancer survivors aged 18–40 years compared a smartphone application with in-person mindfulness-based cessation intervention, specifically addressing geographic reach and depression-related relapse risk ^[78]. Among hospitalized smokers, pooled randomized-trial data evaluated interactive voice-response calls after discharge, including intervention use, satisfaction, and the relationship between call dose and cessation ^[25]B2b. Digital intervention records may help identify early dropout; a 2024 replication study examined whether first-week log-in and engagement data predict withdrawal from multimodal digital cessation programs ^[30]B3b. Telephone callback counseling has also been evaluated using cost-effectiveness and productivity modeling ^[32]B2c.

The workup should end with a documented diagnosis of current tobacco use or abstinence, an assessment of dependence and readiness, relevant comorbidities and contraindication considerations, prior treatment response, objective-verification needs, and a follow-up plan. Dental settings and TB services are additional opportunities to identify tobacco use and connect cessation care with routine treatment ^{[11]B2b[29]A1a[80]}.

Scope and principles

Tobacco-use severity should be assessed as a multidimensional construct rather than inferred from cigarette count alone. Relevant domains include current tobacco-product pattern, nicotine dependence, consumption intensity, duration of use, prior quit attempts, motivation or readiness to quit, co-occurring medical and psychiatric conditions, and social barriers to treatment ^[18]C4[81]. The available evidence does not establish a single validated staging system that applies across all tobacco users; therefore, classification should be used to match treatment intensity and follow-up rather than to deny treatment to people with lower apparent severity ^{[18]C4[33]A1a[5]A1a}.

Product use and exposure severity

Begin by documenting whether the person is a non-user, a single-product user, or a poly-tobacco user, because national survey research has used these categories to characterize tobacco-use patterns ^[37]C4. Record the specific products used, frequency of use, quantity, duration, route of nicotine exposure, and whether combustible tobacco is used; adults with psychotic disorders may use multiple tobacco products and have clinically important nicotine dependence ^[18]C4. Poly-tobacco use, persistent daily use, and continued exposure despite tobacco-related disease should generally be treated as markers for a more intensive assessment, although the cited studies do not define universal numerical cutoffs for these categories ^[18]C4[37]C4.

Nicotine-dependence severity

Nicotine dependence should be assessed directly rather than estimated solely from diagnosis, demographic characteristics, or reported motivation. The Fagerström Test for Nicotine Dependence was used to measure tobacco dependence in caregivers of patients with severe mental disorders, demonstrating its applicability as a structured dependence measure in psychiatric and family-care settings ^[35]C4. In adults with a history of psychosis, nationally representative data specifically examined nicotine-dependence severity and cessation methods, supporting separate documentation of dependence burden in this high-risk population ^[18]C4. Dependence severity should be interpreted alongside psychiatric symptoms, medication use, cognitive impairment, and the person’s ability to engage with treatment, because these factors may affect cessation planning even when dependence scores are similar ^[18]C4[35]C4.

Readiness and cessation-stage stratification

Readiness to quit is a clinically relevant staging dimension. A longitudinal study allocated routine minimum intervention to smokers with mild addiction or those not in the preparation stage, while nicotine-replacement therapy was provided to patients with moderate-to-high dependence and/or high tobacco consumption ^[81]. In that cohort, 29.6% of the 267 participants followed for 5 years remained abstinent, indicating that long-term maintenance—not only initial cessation—should be included in outcome assessment ^[81]. However, this allocation model was quasi-experimental and should not be interpreted as a universal treatment threshold ^[81].

Patients who are not ready to quit should still receive brief motivational intervention, risk communication, and reassessment, while those preparing to quit should receive a concrete quit plan and evidence-based pharmacotherapy or behavioral support when appropriate ^{[5]A1a[33]A1a[34]D5}. The emergency-department INITIATE study protocol illustrates a proactive, multicomponent “quit card” approach designed for a setting where limited time, motivation, and incentives can impede treatment delivery; because it is a protocol, it does not provide efficacy results ^[34]D5.

Disease- and symptom-based risk stratification

Tobacco cessation is particularly urgent when smoking coexists with pulmonary disease. In smokers with COPD or fixed airflow obstruction, investigators evaluated respiratory and bronchitic symptoms, pulmonary-function markers, and intention to quit within the next 30 days, reflecting the importance of integrating symptoms and objective disease severity into cessation assessment ^[38]C4. Smoking is also associated with increased tuberculosis infection risk, recurrent disease, mortality, loss to follow-up, greater disease severity, drug resistance, and slower smear conversion; consequently, active pulmonary tuberculosis should prompt intensified cessation support and follow-up ^[33]A1a. The Cochrane review identified cessation interventions as potentially relevant to tuberculosis treatment outcomes, relapse, and future lung disease, but its abstract does not establish a definitive intervention effect for every outcome ^[33]A1a.

Psychosocial and comorbidity risk

Risk stratification should account for populations facing disproportionate tobacco-related harm or barriers to care. Adults experiencing homelessness have high tobacco-use rates, substantial cessation barriers, and tobacco-related morbidity and mortality; interventions in this population should therefore assess access to treatment, housing instability, competing substance use, and continuity of follow-up ^[5]A1a. Adults with psychotic disorders have high smoking prevalence and premature mortality, making psychiatric history a risk marker for intensified assessment and integrated cessation care ^[18]C4. Severe mental-disorder research has also examined whether caregiver tobacco dependence, measured with the Fagerström test, modifies the relationship between psychiatric symptom severity and caregiver abuse; this supports considering household tobacco dependence and safety context during assessment, although the cross-sectional design cannot establish causality ^[35]C4.

Tobacco use has additionally been studied in relation to postpartum-depression symptom severity in a large PRAMS analysis, and among U.S. veterans in relation to disability-related functional difficulties and single- versus poly-product use ^[36]C4[37]C4. These findings support incorporating reproductive mental health, disability, and functional limitations into individualized risk assessment, while recognizing that the cited cross-sectional studies establish associations rather than causal pathways ^[36]C4[37]C4.

Practical risk tiers

A pragmatic approach is to classify risk as higher when severe dependence, poly-tobacco use, psychotic or severe mental disorder, homelessness, active tuberculosis, COPD or respiratory symptoms, postpartum depressive symptoms, disability-related functional difficulty, or repeated unsuccessful quit attempts are present ^{[5]A1a[18]C4[33]A1a[36]C4[37]C4[38]C4[81]}. Risk tiering should trigger proportional treatment intensity, proactive outreach, relapse-prevention planning, and repeated reassessment rather than a one-time judgment of cessation potential ^{[5]A1a[18]C4[33]A1a[81]}.

Scope and timing

Acute-care encounters—including emergency departments (EDs), inpatient wards, pediatric EDs, psychiatric hospitals, and community assistance settings—are opportunities to identify tobacco use and initiate cessation support, particularly because tobacco-use prevalence is higher among ED patients than in the general population and because people living in poverty experience disproportionate tobacco-related harm.^{[42]D5[40]A1b} Management should be brief, structured, and linked to continuing support rather than deferred until a dedicated primary-care visit.^{[42]D5[40]A1b}

Immediate assessment: Ask and Advise

Use the 5 A’s: Ask, Advise, Assess, Assist, and Arrange as the organizing framework for acute-care tobacco treatment.^[83] At minimum, identify current tobacco use and provide clear, personalized advice to stop.^[15]C4[39]C4 In a pediatric ED study, the intervention specifically used the first 2 A’s—Ask and Advise— followed by a fax referral to the state tobacco quitline for smoking parents accompanying children.^[15]C4

Provider implementation is inconsistent. In a multicenter survey of 800 ED clinicians, respondents reported their strongest adherence to asking about tobacco use, while adherence to the remaining guideline elements was less complete.^[39]C4 Acute-care nursing practice has likewise been examined against the 5 A’s framework, with individual and organizational characteristics associated with intention to integrate cessation intervention into routine practice.^[83] These findings support standardized prompts, staff training, and organizational workflows rather than relying solely on individual clinician initiative.^[39]C4[83]

Brief intervention and referral

When time, motivation, or clinical workload limits counseling, deliver a concise intervention and make a direct referral. A randomized 2007 pilot assigned 295 smokers seeking emergency assistance from Salvation Army community organizations to either a 30-second smoking intervention or no intervention; follow-up assessed satisfaction with the agency and interest in tobacco cessation.^[40]A1b This model demonstrates that tobacco treatment can be embedded in nonmedical community encounters serving people who may be missed by conventional cessation services.^[40]A1b

In rural emergency care, a 1-hour asynchronous training programme taught 13 ED nurses a brief smokeless-tobacco intervention using the 2-A and 1-R approach: Ask, Advise, and Refer.^[19]C4 Pre- and post-training testing showed significant improvement, supporting brief, scalable education for clinicians who manage smokeless-tobacco users.^[19]C4 The reported study rationale also notes that a brief intervention of one minute or less can increase quit-attempt rates threefold; this claim comes from the study background and should not be interpreted as a treatment effect established by that training evaluation itself.^[19]C4

Referral should be proactive whenever possible. The pediatric ED intervention used fax referral to a state quitline rather than relying on the parent to seek help independently.^[15]C4 A proposed multicenter ED randomized trial—the INITIATE trial—was designed to test a simple, proactive, multicomponent “quit card” intervention against usual care, specifically to address the ED constraints of limited time, low motivation, and lack of incentives.^[34]D5 Because the cited article is a trial protocol, it provides no effectiveness results.^[34]D5

Hospital and psychiatric settings

For admitted smokers, continue treatment beyond the acute encounter. A hospital-initiated Ottawa Model intervention was evaluated among 1,367 adults recruited during admission to 14 Ontario hospitals: 726 received the intervention and 641 received usual care.^[44]B2b Participants were linked to administrative healthcare data for two years, and the intervention group experienced significantly lower all-cause readmission rates.^[44]B2b This supports integrating cessation treatment into hospitalization and arranging follow-up after discharge, although the supplied evidence does not provide a medication-specific regimen or complete outcome estimates.^[44]B2b

Inpatient psychiatry is an important setting because smoking causes substantial preventable morbidity and mortality among people with severe mental illness, whose smoking rates are disproportionately high and abstinence rates are low.^[41]A1a The 2026 Cochrane review identified psychiatric hospitalization—particularly in smoke-free hospitals—as an opportunity to promote and support cessation and was designed to assess intervention effects in adults with severe mental illness.^[41]A1a The supplied abstract does not report the review’s effect estimates; therefore, acute psychiatric management should emphasize systematic identification, advice, assistance, and post-discharge arrangement without attributing a specific intervention effect to this review.^[41]A1a

Special considerations and limitations

Parents who smoke while accompanying children may accept ED-based cessation care, making pediatric visits a practical point for brief intervention and quitline linkage.^[15]C4 Community organizations can also reach smokers living in poverty who may not be reached by standard healthcare delivery.^[40]A1b Tobacco and alcohol use may co-occur, and social-media analyses have examined tobacco-related discussion in intoxication-related alcohol contexts, including perceptions of nicotine use while drinking and alcohol-associated failed quit attempts.^[43]D5 The cited social-media study is observational and does not establish an acute treatment strategy or causal effect.^[43]D5

A systematic review of adult and pediatric ED cessation interventions searched MEDLINE and CINAHL through February 2014 and evaluated interventions initiated in emergency settings.^[42]D5 Its existence supports an evidence-informed ED approach, but the supplied abstract does not provide pooled results or a definitive estimate of benefit.^[42]D5 Accordingly, acute management should prioritize feasible Ask–Advise–Refer/Assist–Arrange workflows, direct quitline or community referral, staff training, and continuity after discharge, while avoiding unsupported claims about a particular counseling duration, medication, or quit rate.^{[15]C4[19]C4[34]D5[39]C4[42]D5[44]B2b}

Treatment objectives and longitudinal approach

Long-term management should aim for sustained abstinence from all tobacco products, while recognizing that tobacco dependence commonly requires repeated, structured treatment rather than a single brief intervention. Tobacco use remains a major preventable cause of disease, disability, and death, and smoking during pregnancy is associated with miscarriage, congenital anomalies, sudden infant death syndrome, and impaired childhood lung function ^[45]A1c. The 2021 US Preventive Services Task Force (USPSTF) evidence review evaluated behavioral interventions, pharmacotherapy, and electronic cigarettes for cessation in adults, including pregnant persons ^[46]A1a.

At every clinically appropriate encounter, document current tobacco use, prior quit attempts, motivation, treatment preferences, withdrawal or relapse history, and use of cigarettes, smokeless tobacco, or other nicotine products. Accurate longitudinal documentation is important because incomplete smoking histories can limit identification of patients eligible for cessation treatment and lung-cancer screening ^[86]. Digital outreach using patient portals or SMS has been studied as a means of improving the completeness of smoking histories, although the supplied evidence does not establish that one approach is superior for long-term cessation ^[86].

Behavioral and pharmacologic treatment

Behavioral counseling and pharmacotherapy should be considered complementary components of definitive treatment. The USPSTF review specifically assessed the effectiveness and safety of both approaches, as well as electronic cigarettes, and the recommendation statement addresses adults and pregnant persons ^{[45]A1c[46]A1a}. Treatment intensity should be matched to dependence severity, previous treatment response, comorbidity, access, and patient preference; follow-up should continue beyond the initial quit attempt to identify relapse and reinitiate treatment when needed ^{[45]A1c[46]A1a}.

Evidence from military populations supports combining behavioral and pharmacological strategies when feasible. A 2025 meta-analysis identified 5 randomized controlled trials involving 2,619 active-duty personnel and veterans and reported a significant increase in 7-day point-prevalence abstinence at short-term follow-up (≤3 months); the review was designed to assess both behavioral and pharmacological interventions ^[16]A1a. These findings support systematic cessation services in military and veteran health systems, while recognizing that short-term abstinence does not by itself establish durable long-term cessation ^[16]A1a.

Combination nicotine-replacement therapy (c-NRT) has also been tested in people living with HIV. In a South African randomized trial, 280 participants were assigned to intensive antismoking behavioral counseling alone or counseling plus nicotine patches augmented by nicotine gum; abstinence at 6 months was validated using exhaled carbon monoxide and urine cotinine ^[26]A1b. The trial directly addresses whether adding c-NRT to intensive counseling improves cessation in a resource-limited HIV-care setting, although the supplied abstract does not provide the comparative effect estimate ^[26]A1b.

Tailored management for clinical and social complexity

People living with HIV have been identified as having smoking rates approximately 2–3 times higher than those in the general population, and a pragmatic three-arm randomized trial in 13 HIV outpatient clinics in Hanoi evaluated behavioral treatment with and without pharmacotherapy ^[9]A1b. The trial enrolled adults who smoked at least one cigarette daily and had regular clinic access, providing evidence relevant to integrating cessation into routine HIV care ^[9]A1b. A preceding implementation case study described theory-driven adaptation of cessation treatment and implementation strategies for HIV outpatient clinics in Vietnam, where cessation services were not routinely available ^[85].

Cancer diagnosis should trigger immediate and sustained cessation support. A systematic review and meta-analysis of randomized trials in non-respiratory cancers evaluated cessation interventions for patients and caregivers, reflecting persistent tobacco use and the need for treatment in breast, prostate, colorectal, cervical, and bladder cancer settings ^[49]A1a. In India, a systematic review of 20 observational studies examined continued smoking, smokeless-tobacco use, or both after cancer diagnosis, underscoring the persistence of tobacco exposure after diagnosis ^[17]B2a. The available abstracts do not provide pooled intervention effects or prevalence estimates and should not be used to infer comparative efficacy ^{[17]B2a[49]A1a}.

People with serious mental illness may require combined behavioral and pharmacological treatment. A pilot randomized trial enrolled 48 adults and compared a 12-week program involving game-based group physical activity, counseling, and pharmacotherapy with sedentary games alongside counseling and pharmacotherapy; the intervention group showed a significant average reduction of 2.9 cigarettes per week over time ^[50]A1b. Because this was a small pilot study, it supports feasibility and the potential value of engagement-oriented adjuncts rather than establishing a definitive long-term treatment effect ^[50]A1b. Contingency management is another possible adjunct for smokers with depressive symptoms; a systematic review identified 6 eligible studies examining abstinence, depressive symptoms, adherence, and tobacco-related outcomes, but the supplied evidence does not report a definitive pooled effect ^[88].

Digital, mobile, and incentive-based maintenance

Digital interventions can extend treatment access and support maintenance after clinical contact. A multicenter randomized trial in Spanish primary care evaluated the Dejal@bot smartphone chatbot against usual clinical practice, while an umbrella review assessed long-term effectiveness and adherence of standalone text-message, smartphone-app, internet-based, and artificial-intelligence modalities using a threshold of ≥6 months ^[53]A1b[87]. These approaches may be used as self-management tools or adjuncts, but digital treatment should not be assumed to replace evidence-based counseling or pharmacotherapy when those services are available ^[87].

For veterans experiencing homelessness, a comparative-effectiveness trial randomized 127 participants to mobile contingency management comprising 4 weeks of mobile incentives, 5 weeks of telehealth counseling, and optional 12 weeks of pharmacotherapy, or Veterans Affairs standard care; participants were followed with biochemically verified abstinence measures and a randomized $100 longer-term incentive at 3 months ^[84]. This model is particularly relevant where transportation, housing instability, and in-person follow-up impede care ^[84].

University students may benefit from tailored programs, but the evidence remains heterogeneous. A systematic review identified 18 studies, with 11 included in meta-analysis, evaluating tobacco cessation programs in university students; risk of bias, heterogeneity, publication bias, and certainty were assessed using Cochrane-oriented methods and GRADE ^[89].

Quality, implementation, and follow-up

Clinicians and reviewers should interpret cessation trials cautiously because attrition, performance bias, detection bias, selective reporting, and other design limitations can materially affect estimates of benefit; Cochrane Tobacco Addiction Group guidance provides tobacco-specific methods for assessing these risks ^[52]D5. Implementation is itself a treatment target: an 8-week WeChat medical-education intervention randomized 1,887 healthcare providers and followed them for 34 weeks to assess use of standard cessation practices ^[51]A1b. Dentist-delivered behavioral support for smokeless-tobacco cessation has also been evaluated in dental hospitals in Pakistan, where implementation remains limited despite recommendations for oral-health professionals to provide cessation support ^[58]C4. Long-term management should therefore combine repeated assessment, evidence-based behavioral and pharmacologic care, biochemical confirmation when appropriate, and system-level mechanisms that make treatment routinely available ^{[45]A1c[46]A1a[52]D5[58]C4}.

From brief advice to guideline-based treatment

Early tobacco-cessation treatment was organized around systematic identification of tobacco use, brief advice, and referral to more intensive support. The 2009 USPSTF reaffirmation retained a Grade A recommendation to ask all adults about tobacco use and provide cessation interventions to those who use tobacco; it also recommended asking all pregnant women about tobacco use and providing augmented, pregnancy-tailored counseling to those who smoke. ^[60]A1c This recommendation was based on the USPSTF’s review of the 2008 U.S. Public Health Service clinical practice guideline and reaffirmed that the net benefits of cessation interventions in adults and pregnant women were well established. ^[60]A1c

The 2021 USPSTF statement broadened the population framework to include adults who use tobacco, including pregnant persons, and emphasized tobacco use as a leading preventable cause of disease, disability, and death. ^[45]A1c The statement reported that approximately 50.6 million U.S. adults (20.8%) used tobacco in 2019, including 14.0% who currently smoked cigarettes and 4.5% who used electronic cigarettes. ^[45]A1c It also highlighted pregnancy-specific risks, including miscarriage, congenital anomalies, sudden infant death syndrome, and impaired childhood lung function. ^[45]A1c

Expansion of delivery settings and providers

Treatment progressively moved beyond conventional medical consultations. A 2008 pediatric emergency-department intervention applied the first two “A’s”—Ask and Advise—combined with fax referral to a state quitline for smoking parents accompanying children; the study evaluated acceptability among both parents and clinicians. ^[15]C4 Pharmacists also became cessation providers: a U.S. randomized trial compared a pharmacist-delivered face-to-face group program with brief telephone standard care and used biochemical confirmation of abstinence. ^[92]

Community-based delivery was developed to reach populations poorly served by routine healthcare. In a 2007 pilot among smokers seeking emergency assistance from a Salvation Army agency, participants were randomized to a 30-second smoking intervention or no intervention, with satisfaction and interest in cessation assessed during the visit. ^[40]A1b In India, the BABEX cluster-randomized trial assigned 32 low-income administrative blocks and evaluated a brief tobacco-cessation intervention delivered by health workers to 1,213 adult tobacco users. ^[71]A1b A separate four-arm cluster-randomized study among 646 call-centre employees in India evaluated multiple cessation strategies over 18 months, reflecting the adaptation of treatment to occupational settings. ^[93]

Interventions also became more tailored. Qualitative follow-up of participants exposed to lay health influencers found that 86% reported modifying their intervention behavior according to individual smoker characteristics, their relationship with the smoker, or the setting. ^[64]C4 For smokers with low socioeconomic status, proactive outreach using electronic health-record smoking documentation was tested as a strategy to address socioeconomic disparities and offer tobacco treatment directly to disadvantaged smokers. ^[47]A1b

Continuity of care and post-discharge treatment

Hospitalization emerged as a high-yield opportunity to initiate cessation treatment, but subsequent research emphasized that counseling begun in hospital must continue after discharge. The Helping Hand 2 randomized trial enrolled 1,357 daily smokers across three hospitals and compared sustained post-discharge care with standard care after in-hospital counseling; sustained care began at discharge and incorporated referral to a nationally available telephone quitline. ^[63]A1b Interactive voice-response telephone calls were subsequently evaluated as an automated method for maintaining treatment after discharge. A pooled analysis included 878 hospitalized smokers who had received in-hospital counseling and planned to stop smoking after discharge, examining intervention exposure, satisfaction, and the relationship between intervention dose and cessation. ^[25]B2b

Adaptation for mental illness and other high-risk groups

Treatment evolution increasingly recognized that standard interventions may require adaptation for people with serious mental illness. A community mental-health study compared a telephone quitline intervention involving counseling and nicotine replacement therapy with community-based group counseling; at six months, both approaches reduced tobacco use, while participants receiving both services were more likely to achieve a 50% reduction in tobacco use. ^[90] A randomized study in people with schizophrenia and related psychotic disorders assigned 170 participants to a personalized cessation package or brief advice to stop tobacco, with outcomes assessed at baseline and at 1, 3, and 6 months. ^[10]A1b More recently, a pilot randomized trial combined counseling and pharmacotherapy with game-based group physical activity or sedentary games; the intervention consisted of 50-minute sessions three times weekly for 12 weeks, and the sample initially smoked an average of 56.3 cigarettes per week. ^[50]A1b

People living with HIV have also become a specific target population. In South Africa, a randomized trial among 280 people with HIV compared intensive behavioral counseling alone with counseling plus combination nicotine-replacement therapy consisting of nicotine patches augmented by nicotine gum; abstinence at six months was biochemically validated using exhaled carbon monoxide and urine cotinine. ^[26]A1b A pragmatic three-arm randomized trial in 13 outpatient HIV clinics in Hanoi evaluated behavioral cessation interventions with and without pharmacotherapy among adults living with HIV, a population reported to smoke at two to three times the rate of the general population. ^[9]A1b

Digital, mobile, and system-level interventions

The most recent phase has focused on scalability, automation, and implementation. A multicenter randomized trial in Spanish primary care compared the smartphone conversational chatbot Dejal@bot with usual clinical practice as a potentially scalable complement to treatment. ^[53]A1b A systematic review and meta-analysis of randomized trials published since 2005 assessed conversational artificial-intelligence interventions, with sustained abstinence for at least 6 months as the primary outcome. ^[91]

Digital tools have also been used to improve clinician implementation. In China, the randomized “WeChat WeQuit” program delivered smoking-cessation training messages to 942 healthcare providers for 8 weeks, compared with 945 controls, and followed participants for 34 weeks to assess use of standard cessation practices. ^[51]A1b Patient-generated digital data have been tested to improve identification of tobacco use: a pragmatic trial compared electronic-portal questionnaires with SMS text-message surveys among adults aged 50–80 years with a tobacco-use history, addressing incomplete smoking histories that can limit lung-cancer screening and cessation outreach. ^[86]

Overall, treatment has evolved from brief, clinician-initiated advice toward multimodal, continuously supported, and population-tailored care that combines counseling, pharmacotherapy, quitlines, community health workers, proactive electronic outreach, and conversational digital systems. ^{[45]A1c[60]A1c[47]A1b[63]A1b[91]}

Building on the evolution of cessation therapies, the generalist now faces the practical challenge of applying them in the moment, often during a brief clinic visit or an emergency department (ED) encounter where the patient’s readiness to quit is unknown. The core cognitive task is not making a diagnosis of tobacco use (that is trivially established by asking) but rather gauging the patient’s motivational state, selecting the right intervention from a menu of options, and deciding when to escalate to specialist resources. This section outlines the point-of-care tools and referral thresholds that guide that process.

The 5A's as a Point-of-Care Framework

The 5A's (Ask, Advise, Assess, Assist, Arrange) remain the standard of care for identifying and managing tobacco use in any clinical setting. National data show that among smokers who visited a health professional in the past year, 87.9% were asked about tobacco use, 65.8% were advised to quit, and 42.6% were assessed for willingness to quit. Of those who wanted to quit, 78.2% were offered assistance but only 17.5% had follow-up arranged ^[65]C4. The steep drop-off after the first two steps is the chief diagnostic uncertainty: the generalist knows the patient smokes but does not know the patient's stage of change or the intensity of support needed. Systematic application of the full 5A's, not just the easy first steps, is required to close this gap.

Point-of-Care Scores: The 5A's and Beyond

No single validated score replaces the 5A's for the initial encounter. However, the 5A's themselves function as a sequential decision-support tool. At the "Assess" step, a simple question, "Are you willing to try to quit within the next 30 days?", stratifies smokers into those ready for action and those who are precontemplative. For the latter, the generalist should deliver a brief (<3 minutes) motivational intervention emphasizing health risks and the benefits of quitting, which ED providers reported as the most acceptable approach ^[39]C4. For patients who are ready, the generalist moves to "Assist" by offering pharmacotherapy or referral. The 5A's thus serve as both a diagnostic and a triage instrument.

Referral Thresholds

When should the generalist refer to a specialist (e.g., intensive counseling, quitline, or a tobacco treatment specialist)? The evidence does not provide a single numerical threshold, but two practical indicators emerge:

• Patient ready to quit but needs pharmacotherapy: The generalist can prescribe nicotine replacement therapy (NRT) or varenicline themselves. However, a minority of ED providers (35%) are willing to write such prescriptions ^[39]C4, suggesting that a referral to a primary care provider or a phone-based quitline (which can provide pharmacotherapy management ) is a reasonable alternative.
• Multiple failed attempts or psychiatric comorbidity: Referral to a dedicated tobacco cessation program or a specialist in addiction medicine is warranted. The generalist's role is to identify these patients and initiate the referral, not to deliver intensive counseling.

Evidence for ED-Based Interventions

In the ED setting, where diagnostic uncertainty is highest and time is shortest, ED-initiated cessation interventions correlate with higher cessation rates than those reported in national surveys, although no single intervention type has proven superior ^[42]D5. Two studies that did show significant effects both used motivational interviewing -based interventions ^[42]D5. Patient satisfaction with ED-based cessation is >90% ^[42]D5. Therefore, the generalist should not defer cessation counseling simply because of time constraints or uncertainty about the patient's follow-up; even a brief intervention with a referral to the National Toll-Free Smoker's Quitline (used by 84% of ED providers who intervene) is effective ^[39]C4.

Table: 5A's Performance in Clinical Practice

The table illustrates the diagnostic gap: the generalist reliably identifies smokers but fails to systematically assess readiness and arrange follow-up, which are the steps that convert identification into action.

Controversies and Guideline Disagreement

No major guideline disagreement exists on the 5A's framework, but there is debate about the optimal intensity of ED-based interventions. The systematic review ^[42]D5 found no clear superiority of one intervention type, and most individual studies (11/13) did not show significant differences in abstinence. This uncertainty does not invalidate the generalist's role; rather, it underscores that any intervention, brief advice, motivational interviewing, or referral, is better than none, and the choice should be guided by the patient's readiness and the clinician's comfort.

Pearl: The 5A's drop from 88% (Ask) to 18% (Arrange): the generalist who completes all five steps, especially the last two, will close the gap between identification and effective treatment. If uncertain about the patient's readiness, ask once; then act on the answer.

Tobacco-related complications

Tobacco use is a major preventable cause of disease, disability, and death. In the United States, cigarette smoking and secondhand-smoke exposure were estimated to account for approximately 480,000 deaths annually in 2014. ^[45]A1c Smoking is also associated with substantial perioperative risk, including an increased risk of postoperative complications; this risk is the principal rationale for offering cessation treatment before surgery. ^{[66]A1a[67]D5} In patients undergoing bariatric surgery, preoperative tobacco abstinence is considered beneficial for reducing postoperative complications, and some programs require abstinence before scheduling the operation. ^[70]C4

Pregnancy is a particularly important setting because smoking increases the risk of miscarriage and congenital anomalies, as well as adverse outcomes in offspring, including sudden infant death syndrome and impaired childhood lung function. ^[45]A1c The USPSTF therefore identifies pregnant persons who smoke as a population requiring evidence-based behavioral cessation support, with pharmacotherapy decisions requiring individualized consideration because the evidence and risk–benefit balance differ during pregnancy. ^[45]A1c

Perioperative complications and intervention effects

The perioperative period provides an opportunity to reduce smoking-related surgical risk through behavioral counseling, pharmacotherapy, or combined interventions. ^{[66]A1a[67]D5} A 2023 systematic review and meta-analysis included 38 randomized studies involving 7,310 participants and evaluated abstinence at the time of surgery as the primary outcome and abstinence at 12 months as a secondary outcome. ^[66]A1a The review was designed to assess whether cessation interventions improve perioperative abstinence and longer-term cessation; the abstract does not provide pooled numerical estimates for postoperative complications or abstinence, so a specific magnitude of benefit should not be inferred from this reference alone. ^[66]A1a

A contemporaneous systematic-review protocol described the earlier evidence as showing that perioperative interventions increase short-term abstinence and may reduce postoperative complications, while noting that the evidence base had expanded and required updating. ^[67]D5 Accordingly, cessation should be integrated into preoperative assessment rather than treated solely as a requirement for surgery. Mandatory abstinence policies may create access or completion problems: a retrospective bariatric-program study specifically evaluated whether tobacco-use status was associated with completion of a preoperative surgical weight-loss program, reflecting the possibility that tobacco requirements can affect progression through care. ^[70]C4 Because the provided abstract does not report the study’s numerical completion results, it does not establish the size or direction of that association. ^[70]C4

Mental illness, substance use, and metabolic complications

People with serious mental illness have high tobacco-related morbidity and mortality. Their life expectancy is reported to be 15–20 years shorter than that of the general population, and smoking further increases cardiovascular risk and premature death among those who also have type 2 diabetes. ^[69]B3b In an integrated health-care system, a retrospective cohort study examined whether cessation-pharmacotherapy prescribing differed according to serious mental illness among smokers with diabetes; the available abstract identifies the disparity as a clinical concern but does not provide the study’s prescribing estimates or causal conclusions. ^[69]B3b

Mental-health-related barriers may include physiological, psychological, and social challenges, and both consumers and clinicians have identified a need to adapt cessation care to these circumstances. ^[95]D Among adolescents receiving substance-use treatment, tobacco use was markedly prevalent: approximately 67.5% used tobacco at both intake and 12-month follow-up, and tobacco use was reported at roughly four times the rate observed in adolescents in the general population. ^[96]D In that cohort, mood, anxiety, or behavioral-disorder diagnoses were associated with changes in tobacco use, and psychiatric disorder was associated with lower odds of becoming a tobacco nonuser rather than continuing tobacco use (adjusted OR 0.153, 95% CI not provided in the supplied abstract). ^[96]D

Smoking and diabetes also represent a clinically important combined burden. A CDC WONDER analysis of U.S. death certificates from 1999–2024 examined mortality among adults aged ≥25 years with both diabetes mellitus and tobacco-use disorder and evaluated disparities by sex, age, race and ethnicity, urbanization, and geographic region. ^[94] This observational mortality analysis can describe population trends and disparities but cannot by itself demonstrate that a cessation intervention caused a reduction in diabetes-related mortality. ^[94]

Equity and implementation complications

Social disadvantage continues to produce disparities in tobacco use and in access to cessation benefits. ^[68]D5 Traditional cessation interventions and public-health policies have not benefited all populations equitably, whereas mobile-health interventions may improve reach, affordability, scalability, and efficiency for socially disadvantaged groups; these are proposed advantages and should not be interpreted as proof of equal effectiveness in every population. ^[68]D5 Hispanic smokers may also have heterogeneous clinical and social profiles involving nicotine dependence, alcohol use, acculturation, depressive symptoms, weight concern, and drug use, factors that may complicate assessment and tailoring of cessation care. ^[21]C4

Safety and monitoring

The supplied references do not provide comparative rates for adverse effects from individual cessation medications, nor do they establish that cessation pharmacotherapy increases psychiatric destabilization, perioperative complications, or pregnancy complications. ^{[45]A1c[66]A1a[69]B3b} Clinicians should therefore monitor treatment response, psychiatric and substance-use comorbidity, pregnancy status, diabetes, and surgical timing, while avoiding unsupported assumptions that treatment-related harms outweigh the well-established complications of continued tobacco exposure. ^{[45]A1c[66]A1a[69]B3b}

Overall prognosis

Tobacco dependence is a chronic, relapsing condition in which prognosis is shaped by continued exposure, treatment engagement, comorbidity, and the durability of abstinence. The cited evidence supports cessation as beneficial both for prevention of future tobacco-related disease and for improving outcomes after major clinical events, particularly surgery and cancer diagnosis. ^{[66]A1a[28]D5} The peri-operative period is a clinically important opportunity because smoking is associated with a substantially increased risk of postoperative complications, while cessation support can address both short-term surgical risk and long-term health. ^[66]A1a

Cancer and long-term survival

Continuing tobacco use after a cancer diagnosis is common enough to remain a major clinical and public-health concern, and it may adversely affect treatment outcomes and survival. ^[17]B2a The cited umbrella review of 12 meta-analyses found that cessation at or around cancer diagnosis was associated with lower mortality across several tumor types: 15–29% lower mortality in lung cancer, 20% lower mortality in head and neck cancer, and 24% lower mortality in colorectal cancer. ^[28]D5 Suggestive survival benefits were also reported for breast, bladder, and gastrointestinal cancers, although the strongest evidence was for lung and colorectal cancers. ^[28]D5 These findings support integrating structured cessation treatment into routine oncology care rather than treating cessation as unrelated to cancer prognosis. ^[28]D5

People with schizophrenia and related psychotic disorders have particularly poor tobacco-related prognosis: they smoke more heavily, experience approximately twice the mortality rate, and have 10–25 years shorter life expectancy than the general population. ^[10]A1b A personalized cessation package was therefore evaluated against brief advice in a randomized study with outcomes measured through 6 months, illustrating the need for sustained, disorder-sensitive treatment rather than reliance on one-time advice. ^[10]A1b

Peri-operative and hospital-based natural history

A systematic review and meta-analysis identified 38 randomized studies involving 7310 participants evaluating peri-operative tobacco cessation interventions. ^[66]A1a Abstinence at the time of surgery was the primary outcome, and abstinence at 12 months was the secondary outcome, allowing assessment of both immediate peri-operative change and longer-term maintenance. ^[66]A1a Hospitalization similarly provides a “teachable moment,” but interventions initiated during admission require post-discharge continuation to be effective; the Helping Hand 2 trial tested sustained post-discharge care against standard care in 1357 daily smokers. ^[63]A1b

Effectiveness across populations and delivery models

Evidence indicates that intervention effects and implementation may vary by population and setting. A systematic review specifically examined behavioral, pharmacological, and combined cessation interventions among Arab smokers because effectiveness may differ from that observed in predominantly Western study populations. ^[97] In India, the BABEX cluster-randomized trial evaluated a brief, potentially scalable community-outreach intervention delivered by health workers to 1213 adult tobacco users living in low-income communities. ^[71]A1b A meta-analysis of brief behavioral interventions for integrated primary care assessed whether tobacco treatment could be delivered in concise behavioral-health formats. ^[98]

Among people living with HIV, a randomized South African trial compared intensive counseling alone with counseling plus combination nicotine-replacement therapy—nicotine patch augmented by nicotine gum—with abstinence biochemically validated at 6 months using exhaled carbon monoxide and urine cotinine. ^[26]A1b A pragmatic three-arm randomized trial in 13 outpatient HIV clinics in Hanoi compared behavioral cessation interventions with and without pharmacotherapy, addressing the limited evidence on long-term cessation effectiveness in people with HIV in low- and middle-income settings. ^[9]A1b

Digital and remotely delivered interventions may improve reach, but their prognostic value depends on sustained abstinence rather than engagement alone. A primary-care randomized trial evaluated the Dejal@bot conversational chatbot against usual clinical practice. ^[53]A1b A systematic review and meta-analysis of conversational artificial-intelligence interventions specified sustained abstinence for at least 6 months as its primary outcome. ^[91] Among veterans experiencing homelessness, a comparative-effectiveness trial evaluated 4 weeks of mobile contingency management, 5 weeks of telehealth counseling, optional pharmacotherapy, and a longer-term financial incentive for abstinence at 3 months, with follow-up including biochemically verified abstinence. ^[84] Contingency management has also been systematically reviewed in smokers with depressive symptoms, with outcomes including abstinence, depressive symptoms, treatment adherence, and tobacco-related measures. ^[88]

Implementation, equity, and measurement

Health-system implementation influences the natural history of tobacco use by determining whether smokers are identified and offered treatment. In China, the randomized “WeChat WeQuit” medical-education program delivered cessation-training messages to health-care providers for 8 weeks and followed outcomes to 34 weeks, targeting low use of standard cessation practices. ^[51]A1b Proactive outreach through electronic health records was tested among smokers of low socioeconomic status to address disparities associated with slower declines in tobacco use. ^[47]A1b Digital outreach has also been evaluated for improving the completeness of smoking histories, an essential prerequisite for identifying patients eligible for cessation treatment and lung-cancer screening. ^[86]

Dental settings are relevant for smokeless-tobacco prognosis: a Pakistani pragmatic pilot evaluated dentist-delivered behavioral support, while process evaluation examined delivery and implementation of the intervention. ^[58]C4 At the population and health-system levels, reported barriers and facilitators include determinants that affect intervention access, delivery, and success across demographic groups. ^[99] Overall, the most favorable prognosis is associated with early treatment, biochemical or otherwise robust outcome assessment, continuity beyond the initial clinical encounter, and adaptation to social, psychiatric, oncologic, infectious-disease, and housing-related needs. ^{[9]A1b[10]A1b[26]A1b[47]A1b[63]A1b[66]A1a[84][99]}

Pregnancy: clinical importance and universal identification

Tobacco use in pregnancy is a major preventable health concern. Smoking during pregnancy is associated with adverse pregnancy outcomes, including miscarriage and congenital anomalies, and with complications in offspring such as sudden infant death syndrome and impaired childhood lung function. Among U.S. women who gave birth in 2016, 7.2% reported smoking cigarettes during pregnancy. ^[45]A1c The 2009 U.S. Preventive Services Task Force (USPSTF) recommendation advised clinicians to ask all pregnant women about tobacco use and provide augmented, pregnancy-tailored counseling to those who smoke; this was classified as a Grade A recommendation. ^[60]A1c

The 2021 USPSTF statement continued to address tobacco cessation interventions in adults, including pregnant persons. ^[45]A1c Its accompanying evidence review evaluated behavioral interventions, pharmacotherapy, and electronic cigarettes for cessation among adults, including pregnant persons, using systematic reviews and randomized clinical trials identified through September 25, 2020. ^[46]A1a Accordingly, tobacco-use assessment should be incorporated into routine prenatal care, with counseling adapted to pregnancy and repeated opportunities for cessation support. ^{[45]A1c[60]A1c}

Behavioral support and treatment selection

Pregnancy-tailored counseling is the most clearly supported intervention in the supplied recommendations. ^[60]A1c Counseling should be individualized to the pregnant person's tobacco product, readiness to stop, social circumstances, and coexisting mental-health or substance-use concerns; however, the references supplied here do not establish that any particular counseling format, medication, dose, or electronic-cigarette product is preferred during pregnancy. The 2021 evidence review specifically examined pharmacotherapy and electronic cigarettes, but the supplied abstract does not provide comparative efficacy or safety estimates for these options in pregnant persons. ^[46]A1a

Clinicians should therefore avoid assuming that electronic cigarettes are harmless or equivalent to evidence-based cessation treatment during pregnancy. Electronic-cigarette use was specifically included among the interventions reviewed by the USPSTF evidence report, and concerns about use among women of child-bearing age have been highlighted in perinatal research. ^[46]A1a[100] Counseling should focus on cessation of tobacco exposure rather than substituting one unproven or potentially harmful product for another. This statement is a clinical interpretation of the scope of the cited evidence, not a claim that the supplied references establish a definitive risk estimate for electronic cigarettes. ^[46]A1a[100]

Mental health and postpartum considerations

Mental-health symptoms may identify a group requiring enhanced, coordinated cessation support. In a population-based analysis of 34,633 women with live births from the 2009–2011 Pregnancy Risk Assessment Monitoring System, smoking before and during pregnancy and prenatal cessation were compared between women reporting depression or anxiety and those not reporting these conditions. ^[73]C4 The study was cross-sectional and observational; therefore, it describes associations and cessation patterns rather than proving that depression or anxiety causes continued smoking or that treatment of either condition produces cessation. ^[73]C4

Postpartum mental health should also be considered when maintaining cessation support after delivery. A 2025 PRAMS analysis included 218,128 mothers from 2015–2020 and examined associations between recent tobacco use and levels of postpartum-depression symptoms using multinomial regression and sensitivity analyses for unmeasured confounding. ^[36]C4 Because this was a cross-sectional analysis, the reported associations should not be interpreted as evidence of causality. ^[36]C4 Nonetheless, tobacco status and postpartum-depression symptoms should be assessed together when planning continued behavioral support. ^[36]C4

Co-occurring alcohol or other substance use

Pregnant women who use alcohol or other psychoactive substances represent a particularly vulnerable population. A systematic-review protocol reported tobacco-use prevalence estimates of 71%–95% among pregnant women with co-occurring substance-use problems and noted that relatively few successfully stop smoking during pregnancy despite the availability of evidence-based cessation treatments. ^[72]D5 The cited article is a protocol, not a completed effectiveness review; it therefore identifies an evidence gap and does not establish the superiority of a specific behavioral or pharmacological intervention for this group. ^[72]D5 Assessment and treatment planning should address tobacco use alongside other substance use rather than treating cessation in isolation. ^[72]D5

Social, cultural, and geographic considerations

Interventions should be adapted for populations experiencing social or health inequities. A Romanian formative study of 143 pregnant women examined partner support and relationship characteristics as potential correlates of smoking cessation during pregnancy; it was conducted to inform development of a couple-focused cessation trial, so it does not demonstrate the effectiveness of couple-based treatment. ^[74]C4 Partner involvement may nevertheless be considered when desired by the pregnant person and when it is safe and supportive. ^[74]C4

Among Alaska Native and American Indian women, tobacco use during pregnancy was identified as prevalent, including cigarette smoking and smokeless tobacco use such as Iqmik. A social-marketing intervention developed culturally relevant communication messages through qualitative focus groups and interviews (n=60) followed by quantitative survey interviews (n=52). ^[101]D This work describes message development rather than cessation efficacy; culturally grounded, community-informed communication should therefore be viewed as an implementation strategy, not as proven standalone treatment. ^[101]D

Evidence and policy transfer to low- and middle-income countries (LMICs) require caution. A qualitative case study reported limited evidence for interventions to reduce tobacco use among pregnant women in LMICs and examined how health-economic evidence, largely produced in high-income countries, might inform policy. ^[75]D5 Resource availability, local tobacco products, health-system capacity, and cultural context should be considered when adapting pregnancy cessation programs. ^[75]D5

Preventive assessment and documentation

Tobacco use should be assessed and documented systematically at healthcare encounters, including combustible cigarettes, smokeless tobacco, e-cigarettes, heated tobacco, and other nicotine products, because incomplete smoking histories in the electronic medical record can limit access to cessation care and lung cancer screening. ^[86] Patient-generated health data may improve documentation: a pragmatic randomized trial among English-preferring adults aged 50–80 years with a history of tobacco use compared electronic portal questionnaires with SMS text-message surveys and evaluated message framing and completeness of smoking histories. ^[86] The supplied abstract does not report the comparative results; therefore, digital collection should complement, rather than replace, clinical verification. ^[86]

Assessment should also identify populations with elevated barriers or tobacco burden, including people living with HIV, patients with cancer, adults with serious mental illness, veterans experiencing homelessness, surgical patients, and people using smokeless or noncombustible nicotine products. ^{[26]A1b[49]A1a[50]A1b[84][102][104][106][107]} National ambulatory-care data indicate that smokers with behavioral-health and substance-use conditions may not receive cessation treatment consistently during healthcare visits, underscoring the need to integrate tobacco treatment into routine care rather than restricting it to dedicated cessation encounters. ^[107]

Brief intervention and treatment delivery

Every identified tobacco user should receive clear cessation advice, assessment of readiness, assistance with a quit plan, and follow-up; counseling should be combined with evidence-based pharmacotherapy when clinically appropriate. The evidence supplied supports multicomponent approaches that integrate behavioral counseling, medication, and structured follow-up across clinical settings. ^{[26]A1b[49]A1a[50]A1b[63]A1b[76]A1a[84][102][104]}

Hospitalization and surgery are important opportunities to initiate treatment, but intervention must continue after discharge. In the Helping Hand 2 randomized clinical trial, 1,357 daily smokers hospitalized at three hospitals received in-hospital counseling and were randomized to sustained post-discharge care or standard care; sustained care began at discharge and incorporated referral to a telephone quitline. ^[63]A1b A pooled analysis of two randomized trials involving 878 hospitalized smokers evaluated automated interactive voice-response calls after discharge; all participants had received hospital counseling and planned to stop smoking. ^[25]B2b These studies support using quitlines, automated calls, and other longitudinal contacts to maintain treatment after the patient leaves the hospital. ^{[25]B2b[63]A1b}

Health-professional education is a systems-level prevention strategy. A systematic review and meta-analysis of 28 randomized trials involving 4,343 health-professional students and 3,122 patients found that tobacco-dependence education was evaluated across 16 health-professional programs, with outcomes including student knowledge, self-efficacy, delivery of cessation interventions, and patient cessation. ^[76]A1a Training should therefore be embedded in entry-level professional education and reinforced through clinical workflows. ^[76]A1a Underbilling for eligible cessation counseling has also been identified as a systems problem in a retrospective analysis of an eight-hospital health system, suggesting that accurate coding and reimbursement processes may help support implementation. ^[103]

Special populations

For people with HIV, intensive counseling plus combination nicotine-replacement therapy (nicotine patch augmented by nicotine gum) was tested against intensive counseling alone in an open-label randomized trial in South Africa. ^[26]A1b The trial randomized 280 participants and assessed abstinence at six months using self-report with biochemical validation by exhaled carbon monoxide and urine cotinine. ^[26]A1b HIV clinics may be suitable venues for integrated tobacco-dependence treatment; a Vietnam case study describes adaptation and implementation evaluation of cessation interventions within outpatient HIV clinics, where cessation services were previously unavailable. ^[85]

Cancer care should include cessation intervention at diagnosis and throughout treatment. A systematic review and meta-analysis of randomized trials evaluated cessation interventions among patients and caregivers affected by non-respiratory cancers, including breast, prostate, colorectal, cervical, and bladder cancers. ^[49]A1a An umbrella review of 12 meta-analyses reported that cessation after cancer diagnosis was associated with lower mortality, including reductions of 15–29% in lung cancer, 20% in head and neck cancer, and 24% in colorectal cancer; suggestive benefits were also reported for breast, bladder, and gastrointestinal cancers. ^[28]D5 Continued tobacco use after cancer diagnosis remains common in India: a systematic review identified 20 observational studies estimating post-diagnosis use of smoking, smokeless tobacco, or both among adults with cancer. ^[17]B2a

Adults experiencing homelessness may benefit from low-barrier, technology-enabled care. In a randomized comparative-effectiveness trial of 127 veterans experiencing homelessness, mobile contingency management included four weeks of mobile incentives, five weeks of telehealth counseling, and optional 12-week pharmacotherapy; standard care consisted of three biweekly group sessions and clinically appropriate pharmacotherapy. ^[84] Participants were also randomized to a $100 longer-term financial incentive for abstinence at three months. ^[84]

Adults with serious mental illness require combined behavioral and pharmacological support. A pilot randomized trial used game-based group physical activity three times weekly for 12 weeks alongside counseling and pharmacotherapy, compared with sedentary games; among 48 participants, baseline smoking averaged 56.3 cigarettes per week and smoking declined by an average linear rate of 2.9 cigarettes per week. ^[50]A1b The pilot design and small sample require cautious interpretation. ^[50]A1b

Digital, smokeless-tobacco, and novel-product cessation

Digital cessation tools may be offered as self-management aids or adjuncts to counseling. An umbrella review assessed long-term effectiveness and adherence of standalone text messaging, smartphone applications, internet programs, and artificial-intelligence-based modalities, defining long-term outcomes as at least six months; 45 systematic reviews were qualitatively synthesized using AMSTAR-2. ^[87] The supplied abstract does not establish that one digital modality is superior, so digital care should be selected according to access, preference, adherence, and clinical need. ^[87]

Smokeless-tobacco cessation is an essential component of health maintenance because smokeless tobacco is associated with serious adverse outcomes, including oral cancer and myocardial disorders. ^[102] A systematic review identified 59 intervention studies involving approaches such as brief advice, quitlines, nicotine-replacement therapy, bupropion, varenicline, and mHealth interventions. ^[102] Evidence should be individualized by product, dependence severity, and availability of pharmacotherapy. ^[102]

For adolescents and young adults aged 15–25 years, cessation of e-cigarettes, heated tobacco, and smokeless nicotine products should be addressed separately from prevention of initiation. A systematic review specifically evaluated randomized trials of cessation interventions for these noncombustible products and excluded studies focused on preventing initiation or conventional-cigarette cessation. ^[106] The evidence base remains distinct from adult cigarette-cessation evidence and should not be assumed to be interchangeable. ^[106]